Latest news and press releases about LENSAR Inc (LNSR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.
Price
| Price | $7.09 |
| Market Cap | $87M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 5.44 |
| Price / Book | 5.70 |
| EV / EBITDA | 2.65 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 10380.25% |
| Return on Invested Capital | -16.02% |
| Return on Assets | 49.88% |
| Gross Margin | 47.96% |
| Operating Margin | -13.48% |
| Net Margin | 57.57% |
Related companies: ANIK · ARAY · AVR · CRBP · CRDF · MXCT · OWLT
Explore sector: Healthcare · Medical - Devices
More sections of LNSR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks